活性氧物种驱动的原药基纳米尺度载体用于变革性疗法
Shyam Vasvani1,2, Arathy Vasukutty1, Rizia Bardhan3
1Department of Biomedical Sciences and BioMedical Sciences Graduate Program (BMSGP), Chonnam National University Medical School, Gwangju 61469, Republic of Korea. pik96@jnu.ac.kr.
Biomaterials science
|July 23, 2024
概括
反应性氧物种 (ROS) 是疾病的关键. 响应ROS的纳米级载体提供有针对性的药物输送,提高治疗效率和减少ROS相关疾病的副作用.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 反应性氧物种 (ROS) 在许多病理条件中发挥着关键作用,使他们成为重要的治疗点.
- 纳米级载体已经成为药物输送的有希望的工具,提供更好的稳定性和可溶性.
- 特定于特定地点的药物输送对于提高治疗疗效和最大限度地减少非目标效应至关重要.
研究的目的:
- 审查ROS依赖的基于原药的纳米尺度载体的最新进展.
- 检查这些纳米载体在各种生物医学应用中的应用.
- 突出使用ROS激活前药物的组合疗法的潜力.
主要方法:
- 批判性检查最近关于ROS响应纳米颗粒平台的文献.
- 对脂质体,聚合物纳米粒子和无机纳米载体进行ROS触发药物释放的分析.
- 研究涉及ROS激活前药物的组合疗法策略.
主要成果:
- 响应ROS的纳米颗粒平台能够在ROS水平升高的疾病部位准确释放药物.
- 这些平台包括脂质体,聚合物纳米粒子和无机纳米载体.
- 组合疗法在治疗复杂疾病方面具有协同作用的潜力.
结论:
- 基于ROS依赖的前药物纳米颗粒系统具有巨大的潜力,可以彻底改变生物医学应用.
- 这些系统有助于选择性,可控的药物输送,降低毒性.
- 通过有针对性的纳米载体策略,可以在与ROS相关的疾病中获得更好的治疗结果.
更多相关视频
相关概念视频
Prodrugs
2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.6K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Phase I Oxidative Reactions: Overview
260
Phase I biotransformation, or functionalization, is a crucial chemical process that converts drugs and other xenobiotics into more water-soluble forms, facilitating expulsion from the body. It involves oxidative, reductive, and hydrolytic reactions that add or unveil polar functional groups on lipophilic substrates. Key players in phase I reactions are the mixed-function oxidases. Situated in liver cell microsomes, these enzymes predominantly carry out drug metabolism. They require molecular...
260
Electron Transport Chain: Complex I and II
12.7K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.7K


